You are here

  • Home
  • Archive
  • Volume 15, Issue 4
  • Tamoxifen, raloxifene and tibolone decrease risk of invasive breast cancer in healthy women but increase risk of thromboembolism (tamoxifen, raloxifene), endometrial cancer (tamoxifen) or stroke (tibolone)

Article Text

Article menu
Download PDFPDF
Therapeutics
Systematic review
Tamoxifen, raloxifene and tibolone decrease risk of invasive breast cancer in healthy women but increase risk of thromboembolism (tamoxifen, raloxifene), endometrial cancer (tamoxifen) or stroke (tibolone)

https://doi.org/10.1136/ebm1044

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests VGV was the protocol chairman for the NSABP Study of Tamoxifen and Raloxifene and an investigator for the NSABP Breast Cancer Prevention Trial, both included in the meta-analysis reviewed here.